L. Daniel Browne
2019
In 2019, L. Daniel Browne earned a total compensation of $4.9M as Former President and Chief Executive Officer at Revance Therapeutics, a 5% increase compared to previous year.
Compensation breakdown
| Option Awards | $2,938,373 |
|---|---|
| Salary | $562,527 |
| Stock Awards | $603,050 |
| Other | $808,619 |
| Total | $4,912,569 |
Browne received $2.9M in option awards, accounting for 60% of the total pay in 2019.
Browne also received $562.5K in salary, $603.1K in stock awards and $808.6K in other compensation.
Rankings
In 2019, L. Daniel Browne's compensation ranked 2,253rd out of 13,971 executives tracked by ExecPay. In other words, Browne earned more than 83.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,253 out of 13,971 | 84th |
Division Manufacturing | 814 out of 5,701 | 86th |
Major group Chemicals And Allied Products | 258 out of 2,200 | 88th |
Industry group Drugs | 209 out of 1,886 | 89th |
Industry Pharmaceutical Preparations | 153 out of 1,398 | 89th |
Source: SEC filing on March 26, 2020.
Browne's colleagues
We found five more compensation records of executives who worked with L. Daniel Browne at Revance Therapeutics in 2019.
2019
Mark Foley
Revance Therapeutics
Chief Executive Officer
2019
Abhay Joshi
Revance Therapeutics
Chief Operating Officer
2019
Caryn McDowell
Revance Therapeutics
General Counsel
2019
Tobin Schilke
Revance Therapeutics
Chief Financial Officer
2019
Dustin Sjuts
Revance Therapeutics